•Ocugen (OCGN) stock fell after Phase II data for its OCU410 therapy showed a 31% improvement in lesion reduction, which lagged behind earlier results.
•The study concerns gene therapy for eye disease, and current results raised investor concerns despite the recorded improvement.
•Goldman Sachs analysts warned that disruptions in the Strait of Hormuz threaten the global nitrogen fertilizer market, which accounts for 60% of global use.
•Fertilizer accounts for approximately 20% of grain production costs, potentially leading to reduced global crop supply.
•Russia suspended ammonium nitrate exports from March 21 to April 21 to secure domestic supplies.